Senetek, Nastech strike deals for RNAi technology

Senetek has struck a deal to acquire RNAi technology for brain tumors from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences. The deal includes the rights to three anti-aging compounds for skin. The brain tumor technology is designed to inhibit the production of tenascin-C, which is linked to malignancy. "This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well," said CEO Frank Massino. RNAi technology has turned red-hot in the wake of this year's Nobel Prize for the field's pioneers.

- check out the UPI report on Senetek

ALSO: Nastech struck a licensing deal with City of Hope for RNAi technology. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.